Expertise in
6
conditions

Stephanie Harel

Paris, FR 
Expertise in
6
conditions
Paris, FR 

Overview

Stephanie Harel practices practicing medicine in Paris, France.

Ms. Harel is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Plasmacytoma, Relapsed Refractory Multiple Myeloma (RRMM), and Waldenstrom Macroglobulinemia.

She is actively involved in clinical research, co-authoring 66 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Paris, France
Other Locations
Port-saint-louis-du-rhone, France
2 Rue De La Houssinière, BP 32229, 44322 Nantes Cedex 3, Nantes, 44322, France
Bobigny, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation
Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation
Enrollment Status: Completed
Publish Date: December 07, 2021
Intervention Type: Drug
Study Drugs: Brentuximab, Etoposide, Carboplatin, Ifosfamide
Study Phase: Phase 1/Phase 2
A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma
A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: January 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

66 Total Publications

Outcomes of patients with Waldenström macroglobulinemia in ICU: a retrospective multicentric study.
Outcomes of patients with Waldenström macroglobulinemia in ICU: a retrospective multicentric study.
Journal: Journal of critical care
Published: July 01, 2026

Frequently Asked Questions about Stephanie Harel

Is Stephanie Harel a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Stephanie Harel is classified as an Advanced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Stephanie Harel participate in research or clinical trials?

Yes. Stephanie Harel has published 66 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Stephanie Harel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Harel's expertise for a condition
ConditionClose
      View All 25 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile